المؤلفون: A. E. Kalinin, I. G. Avdyukhin, S. N. Nered, N. S. Besova, A. A. Tryakin, E. V. Artamonova, T. A. Titova, E. S. Obarevich, E. O. Ignatova, N. A. Kozlov, O. V. Rossomakhina, N. A. Shishkina, E. S. Kolobanova, O. A. Malikhova, M. G. Abgaryan, M. P. Nikulin, P. P. Arkhiri, L. A. Vashakmadze, I. N. Peregorodiev, E. A. Suleimanov, I. S. Stilidi, А. Е. Калинин, И. Г. Авдюхин, С. Н. Неред, Н. С. Бесова, А. А. Трякин, Е. В. Артамонова, Т. А. Титова, Е. С. Обаревич, Е. О. Игнатова, Н. А. Козлов, О. В. Россомахина, Н. А. Шишкина, Е. С. Колобанова, О. А. Малихова, М. Г. Абгарян, М. П. Никулин, П. П. Архири, Л. А. Вашакмадзе, И. Н. Перегородиев, Э. А. Сулейманов, И. С. Стилиди

المصدر: Malignant tumours; Том 13, № 4 (2023); 7-17 ; Злокачественные опухоли; Том 13, № 4 (2023); 7-17 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: FOLFIRINOX, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, FLOT, аденокарцинома желудка, аденокарцинома кардиоэзофагеального перехода

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1273/911; Al-Batran SE, Homann N, Pauligk C. et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4) : a randomised, phase 2 / 3 trial. Lancet. 2019 May 11; 393 (10179) : 1948–1957. doi:10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11. PMID: 30982686.; Al-Batran SE, Hofheinz RD, Pauligk C et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO) : results from the phase 2 part of a multicentre, open-label, randomised phase 2 / 3 trial. Lancet Oncol. 2016 Dec; 17 (12) : 1697–1708. doi:10.1016/S1470-2045(16)30531-9. Epub 2016 Oct 22. PMID: 27776843.; Stark AP, Ikoma N, Chiang YJ et al. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol. 2019 Oct; 26 (11) : 3602–3610. doi:10.1245/s10434-019-07638-8. Epub 2019 Jul 26. PMID: 31350645.; Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994; 73 : 2680–6.; Lauren P. The two histological main types of gastric carcinoma : diff use and so-called intestinal-type carcinoma. An attempt at a histo-clinical classifi cation. Acta Pathol Microbiol Scand 1965; 64 : 31–49.; Dindo D, Demartines N, Clavien PA. Classification of surgical complications : a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004; 240 (2) : 205–213.; Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M. et al. Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136 : E359–86).; Cunningham D, Allum WH, Stenning SP, Thompson JN, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355 : 11–20.; Ychou,M, Boige, V, Pignon,J-P, Conroy T,et al. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma : An FNCLCC and FFCD Multicenter Phase III Trial. J Clin Oncol 29 : 1715–1721).; Трусилова, Е. Эффективность и токсичность химиотерапии по схеме FOLFIRINOX у больных диссеминированным раком желудка. Предварительные результаты / Е.В. Трусилова, Н.С. Бесова, В.А. Горбунова и др. // Эффективная фармакотерапия. Онкология, гематология, радиология .– 2013 .– Т. 46 (4) .– С. 6–13.; International Union Against Cancer (UICC). TNM Classification of Malignant Tumours, 7th ed. Sobin L.H., Gospodarowicz M.K., Wittekind Ch., eds. New York : Wiley-Blackwell; 2009.; https://www.malignanttumors.org/jour/article/view/1273

الاتاحة: https://www.malignanttumors.org/jour/article/view/1273
https://doi.org/10.18027/2224-5057-2023-13-4-7-17

المؤلفون: I. E. Khatkov, S. R. Abdulkhakov, S. A. Alekseenko, I. D. Amelina, D. N. Andreev, E. V. Artamonova, N. V. Bakulina, N. S. Besova, L. V. Bolotina, D. S. Bordin, O. S. Vasnev, L. Yu. Vladimirova, Z. V. Galkova, B. I. Dolgushin, L. G. Zhukova, E. O. Ignatova, R. E. Izrailov, V. A. Isakov, A. E. Kalinin, A. M. Karachun, G. G. Karmazanovskii, S. V. Kashin, V. A. Kachenko, V. A. Kim, P. V. Kononets, L. N. Kostyuchenko, T. N. Kuzmina, Yu. V. Kulezneva, S. A. Kurilovich, Yu. A. Kucheryavii, M. A. Livzan, V. K. Lyadov, I. V. Maev, O. A. Malikhova, B. M. Medvedeva, V. M. Moiseenko, S. V. Morozov, I. Yu. Nedolugko, M. F. Osipenko, E. V. Parfenchikova, V. D. Pasechnikov, S. S. Pirogov, I. A. Pokataev, S. A. Protcenko, A. B. Ryabov, N. E. Semenov, E. N. Solodinina, Yu. G. Starkov, I. S. Stilidi, D. L. Stroyakovskii, O. B. Tkachenko, A. A. Tryakin, S. А. Tjulandin, А. А. Fedenko, M. Yu. Fedyanin, S. G. Homeriki, V. M. Homyakov, V. V. Tsvirkun, V. V. Tsukanov, L. N. Shevkunov, K. V. Shishin, V. V. SHCHadrova, Yu. V. Embutnieks, И. Е. Хатьков, С. Р. Абдулхаков, С. А. Алексеенко, И. Д. Амелина, Д. Н. Андреев, Е. В. Артамонова, Н. В. Бакулина, Н. С. Бесова, Л. В. Болотина, Д. С. Бордин, О. С. Васнев, Л. Ю. Владимирова, З. В. Галкова, Б. И. Долгушин, Л. Г. Жукова, Е. О. Игнатова, Р. Е. Израилов, В. А. Исаков, А. Е. Калинин, А. М. Карачун, Г. Г. Кармазановский, С. В. Кашин, В. А. Кащенко, В. А. Ким, П. В. Кононец, Л. Н. Костюченко, Т. Н. Кузьмина, Ю. В. Кулезнева, С. А. Курилович, Ю. А. Кучерявый, М. А. Ливзан, В. К. Лядов, И. В. Маев, О. А. Малихова, Б. М. Медведева, В. М. Моисеенко, С. В. Морозов, И. Ю. Недолужко, М. Ф. Осипенко, Е. В. Парфенчикова, В. Д. Пасечников, С. С. Пирогов, И. А. Покатаев, С. А. Проценко, А. Б. Рябов, Н. Е. Семенов, Е. Н. Солодинина, Ю. Г. Старков, И. С. Стилиди, Д. Л. Строяковский, О. Б. Ткаченко, А. А. Трякин, С. А. Тюляндин, А. А. Феденко, М. Ю. Федянин, С. Г. Хомерики, В. М. Хомяков, В. В. Цвиркун, В. В. Цуканов, Л. Н. Шевкунов, К. В. Шишин, В. В. Щадрова, Ю. В. Эмбутниекс

المصدر: Malignant tumours; Том 13, № 2 (2023); 56-68 ; Злокачественные опухоли; Том 13, № 2 (2023); 56-68 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: скрининг и профилактика рака желудка, gastric cancer prevention, gastric cancer diagnosis, gastric cancer treatment, рак желудка, хирургическое лечение рака желудка, инструментальная диагностика рака желудка, лекарственное лечение рака желудка

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/1091/787; Hamashima C; Systematic Review Group and Guideline Development Group for Gastric Cancer Screening Guidelines. Update version of the Japanese Guidelines for Gastric Cancer Screening. Jpn J Clin Oncol. 2018 Jul 1; 48 (7) : 673-683. doi:10.1093/jjco/hyy077. PMID: 29889263.; Qiu H, Zhou Z. [Updates and interpretation on NCCN clinical practice guidelines for gastric cancer 2017 version 5]. Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Feb 25; 21 (2) : 160-164. PMID: 29492914.; Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep; 27 (suppl 5) : v38-v49. doi:10.1093/annonc/mdw350. PMID: 27664260.; Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021 Jan; 24 (1) : 1-21. doi:10.1007/s10120-020-01042-y. Epub 2020 Feb 14. PMID: 32060757; PMCID: PMC7790804.; Методические рекомендации по оценке достоверности доказательств и убедительности рекомендаций. ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ «Центр экспертизы и контроля качества медицинской помощи» Министерства здравоохранения Российской Федерации (ФГБУ «ЦЭККМП» Минздрава России»). 2017.; Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE : an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336 : 924-6.; Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ 2008; 336 : 1049-51.; Sultan S, Falck-Ytter Y, Inadomi JM. The AGA institute process for developing clinical practice guidelines part one : grading the evidence. Clin Gastroenterol Hepatol 2013; 11 : 329-32.; https://www.malignanttumors.org/jour/article/view/1091

الاتاحة: https://www.malignanttumors.org/jour/article/view/1091
https://doi.org/10.18027/2224-5057-2023-13-2-4

المؤلفون: M. Yu. Fedyanin, F. V. Moiseenko, M. A. Lyadova, V. N. Vorobyeva, V. V. Petkau, A. V. Fateeva, E. S. Kuzmina, O. Yu. Novikova, V. A. Chubenko, N. Kh. Abduloeva, A. A. Kudryavtsev, E. O. Ignatova, R. R. Shakirov, O. A. Pardabekova, L. V. Kindyalova, S. P. Pelikh, O. A. Gladkov, S. A. Tjulandin, A. A. Tryakin

المصدر: Тазовая хирургия и онкология, Vol 11, Iss 1, Pp 11-20 (2021)

مصطلحات موضوعية: colon cancer, antiangiogenic therapy, biosimilars, bevacizumab, avastin, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://ok.abvpress.ru/jour/article/view/491; https://doaj.org/toc/2686-9594

URL الوصول: https://doaj.org/article/ab81d2b18b6d483387d0ba158a69a3b1

المؤلفون: E. O. Ignatova, D. A. Seryak, M. Yu. Fedyanin, A. A. Tryakin, I. A. Pokataev, S. F. Menshikova, Yu. V. Vakhabova, M. S. Karbyshev, K. V. Smirnova, S. A. Tulyandin

المصدر: Успехи молекулярной онкологии, Vol 7, Iss 3, Pp 27-36 (2020)

مصطلحات موضوعية: epstein–bar virus, oncogene, mutation, molecular diagnosis, сirculating dna, immunotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://umo.abvpress.ru/jour/article/view/284; https://doaj.org/toc/2313-805X; https://doaj.org/toc/2413-3787

URL الوصول: https://doaj.org/article/14eaec726b784aa39fac2abcc0fb1713

المؤلفون: T. A. Bogush, A. S. Popova, E. A. Dudko, E. O. Ignatova, B. E. Polotsky, S. A. Tjuljandin, M. I. Davydov

المصدر: Антибиотики и Химиотерапия, Vol 58, Iss 7-8, Pp 40-47 (2020)

مصطلحات موضوعية: discordance, estrogen receptors, breast cancer, metastatic breast cancer, prognosis, therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.antibiotics-chemotherapy.ru/jour/article/view/500; https://doaj.org/toc/0235-2990

URL الوصول: https://doaj.org/article/4ac97a55831a4873850c4cc5d4346603

المؤلفون: M. Yu. Fedyanin, Kh. Kh.-M. El’sunkaeva, I. A. Pokataev, A. A. Tryakin, A. A. Bulanov, O. V. Sekhina, D. A. Chekini, E. O. Ignatova, S. S. Gordeev, V. A. Aliev, D. V. Kuzmichev, Z. Z. Mamedli, M. V. Chernykh, V. V. Glebovskaya, S. I. Tkachev, N. A. Kozlov, S. A. Tjulandin

المصدر: Тазовая хирургия и онкология, Vol 8, Iss 2, Pp 24-37 (2018)

مصطلحات موضوعية: rectal cancer, chemoradiotherapy, adjuvant chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://ok.abvpress.ru/jour/article/view/248; https://doaj.org/toc/2686-9594

URL الوصول: https://doaj.org/article/149181908ade4da9b4b2d3bbdd53a71c

المؤلفون: M. Yu. Fedyanin, Kh. Kh.-M. El’snukaeva, I. A. Pokataev, A. A. Tryakin, A. A. Bulanov, O. V. Sekhina, D. A. Chekini, E. O. Ignatova, S. S. Gordeev, M. D. Budurova, Z. Mamedli, D. V. Podluzhnyy, N. A. Kozlov, S. A. Tyulyandin

المصدر: Тазовая хирургия и онкология, Vol 8, Iss 1, Pp 34-41 (2018)

مصطلحات موضوعية: colon cancer, kras gene mutations, chemotherapy, oxaliplatin, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://ok.abvpress.ru/jour/article/view/241; https://doaj.org/toc/2686-9594

URL الوصول: https://doaj.org/article/f89e8956f46b4f8ea0792177ea22b12c

المؤلفون: N. G. Yaroslavtseva, D. S. Tikhomirov, T. Yu. Romanova, E. N. Ignatova, T. A. Tupoleva, F. P. Filatov, T. V. Gaponova

المصدر: Вопросы вирусологии, Vol 63, Iss 2, Pp 84-90 (2018)

مصطلحات موضوعية: human herpes virus type 6, viral integration, laboratory diagnosics, Microbiology, QR1-502

وصف الملف: electronic resource

Relation: https://virusjour.crie.ru/jour/article/viewFile/190/100; https://doaj.org/toc/0507-4088; https://doaj.org/toc/2411-2097

URL الوصول: https://doaj.org/article/618b1113353c461796a9ec51f18a4d64

المؤلفون: O. G. Starkova, E. N. Ovchinnikova, D. S. Tikhomirov, O. N. Misko, T. A. Soldatova, A. Yu. Krylova, E. N. Ignatova, T. A. Tupoleva, T. V. Gaponova

المصدر: Russian journal of hematology and transfusiology. 67:492-499

مصطلحات موضوعية: Hematology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::2e4c172b2bb30d468c8ca6f6f3ae5519
https://doi.org/10.35754/0234-5730-2022-67-4-492-499

المؤلفون: V. E. Fedosov, A. V. Fedorova, E. I. Ignatova

المصدر: Arctoa. 31:205-222

مصطلحات موضوعية: Plant Science, Ecology, Evolution, Behavior and Systematics

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::8cf86bdf975a876d3d97a1210306843f
https://doi.org/10.15298/arctoa.31.22

المؤلفون: M. A. Afonina, O. I. Kuznetsova, E. A. Ignatova

المصدر: Arctoa. 31:191-204

مصطلحات موضوعية: Plant Science, Ecology, Evolution, Behavior and Systematics

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::777ebe82e2320e0f7ace1d1d420facdc
https://doi.org/10.15298/arctoa.31.21

المؤلفون: S. Y. Dudov, V. E. Fedosov, E. A. Ignatova, O. I. Ryabenko

المصدر: Arctoa. 31:89-110

مصطلحات موضوعية: Plant Science, Ecology, Evolution, Behavior and Systematics

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::8e3a15cfcced19279f604f573c342ad6
https://doi.org/10.15298/arctoa.31.11

المؤلفون: E. A. Ignatova, I. V. Czernyadjeva, M. S. Ignatov, K. G. Klimova, V. A. Bakalin

المصدر: Arctoa. 31:77-88

مصطلحات موضوعية: Plant Science, Ecology, Evolution, Behavior and Systematics

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::730c01ec383b12b8e5b85c127d601567
https://doi.org/10.15298/arctoa.31.10

المؤلفون: E. V. Sofronova, O. M. Afonina, O. A. Belkina, M. A. Boychuk, V. V. Chakov, I. V. Czeernyadjeva, G. Ya. Doroshina, M. V. Dilun, A. P. Dyachenko, V. E. Fedosov, I. V. Filippov, E. A. Glazkova, O. G. Grishutkin, M. S. Ignatov, E. A. Ignatova, T. G. Ivchenko, A. S. Kartasheva, Kh. M. Khetagurov, N. A. Konstantinova, M. N. Kozhin, V. A. Kuptsova, S. A. Kutenkov, E. Yu. Kuzmina, E. D. Lapshina, M. A. Makarova, A. I. Maksimov, T. Ju. Minayeva, I. A. Nikolayev, N. N. Popova, A. D. Potemkin, D. S. Schuryakov, L. A. Sergienko, A. V. Shkurko, S. A. Suragina, G. S. Taran, V. V. Teleganova, R. A. Tsvizhba, D. Ya. Tubanova

المصدر: Arctoa. 31:227-246

مصطلحات موضوعية: Plant Science, Ecology, Evolution, Behavior and Systematics

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::de58d0e6b5a193f4f0b96514304c7600
https://doi.org/10.15298/arctoa.31.24

المؤلفون: E N Ignatova, T A Tupoleva, E N Ovchinnikova, T Yu Romanova, N G Yaroslavtseva, F P Filatov, V V Troitskaya, L A Kuzmina, E N Parovichnikova, T V Gaponova, V G Savchenko

المصدر: Терапевтический архив, Vol 89, Iss 11, Pp 27-34 (2017)

مصطلحات موضوعية: hepatitis b virus, hepatitis b virus core antigen antibodies, patients with blood system diseases, transfusion mode of transmission, Medicine

وصف الملف: electronic resource

Relation: https://ter-arkhiv.ru/0040-3660/article/viewFile/32293/pdf; https://doaj.org/toc/0040-3660; https://doaj.org/toc/2309-5342

URL الوصول: https://doaj.org/article/1c6b5ee88fd642328a3e68ecd712fa73

المؤلفون: A. A. Tryakin, M. Yu. Fedyanin, A. S. Tsukanov, Yu. A. Shelygin, I. A. Pokataev, E. O. Ignatova, G. G. Khakimova, M. A. Frolova, S. A. Tjulandin, А. А. Трякин, М. Ю. Федянин, А. С. Цуканов, Ю. А. Шелыгин, И. А. Покатаев, Е. О. Игнатова, Г. Г. Хакимова, М. А. Фролова, С. А. Тюляндин

المصدر: Malignant tumours; Том 9, № 4 (2019); 59-69 ; Злокачественные опухоли; Том 9, № 4 (2019); 59-69 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: ипилимумаб, microsatellite instability, MSI-high, immune therapy, nivolumab, pembrolizumab, ipilimumab, mismatch repair deficiency, микросателлитная нестабильность, иммунотерапия, ниволумаб, пембролизумаб

وصف الملف: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/687/482; GM., Li. Mechanisms and functions of DNA mismatch repair. Cell Res 2008; 18: 85 – 98.; Цуканов А. С., Шелыгин Ю. А., Семенов Д. А., с соавт. Синдром Линча. Современное состояние проблемы. Медицинкая генетика, 2017. Т. 16. № 2. С 11 – 18.; Bonadona V, Bonaïti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011;30:2304 – 10.; Alarcon F, Lasset C, Carayol J, et al. Estimating cancer risk in HNPCC by the BRL method. Eur J Hum Genet 2007;15:831 – 6.; Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet 2009;75:141 – 9.; Engel C, Loeffler M, Steinke V, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012;30: 4409 – 15.; Latham A., Srinivasan P, Kemel Y, et al. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. J Clin Oncol 2019, 37 (4): 286 – 299.; Boland C. R., Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010;138 (6):2073 – 87.; Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017; 357: 409 – 413.; Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015; 372: 2509 – 2520.; Dolcetti R, Viel A, Doglioni C, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol 1999; 154: 1805 – 1813.; Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015; 5: 43 – 51.; Lal N, Beggs AD, Willcox BE, et al. An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy. Oncoimmunology. 2015 Apr 2;4 (3):e976052.; Llosa N. J., Cruise M., Tam A. et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015;5 (1):43 – 51.; Fusi A., Festino L., Botti G. et al. PD-L1 expression as a potential predictive biomarker. Lancet Oncol 2015;16 (13):1285 – 7.; Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015 Nov;21 (11):1350 – 6.; Network., Cancer Genome Atlas Research. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202 – 209 (2014).; Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 497:67 – 73, 2013.; Umar A, Boland CR, Terdiman JP, et al. Revised bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261 – 268.; C Luchini, F Bibeau, M J L Ligtenberg, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1 / PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 2019, 30 (8): 1232 – 1243.; Colle R, Cohen R, Cochereau D, et al. Immunotherapy and patients treated for cancer with microsatellite instability. Bull Cancer 2017; 104: 42 – 51.; J., Shia. Evolving approach and clinical significance of detecting DNA mismatch repair deficiency in colorectal carcinoma. Semin Diagn Pathol 2015; 32: 352 – 361.; TA., Mills AM and Longacre. Lynch syndrome screening in the gynecologic tract: current state of the art. Am J Surg Pathol 2016; 40: e35–44.; Mills AM, Sloan EA, Thomas M, et al. Clinicopathologic comparison of lynch syndrome-associated and «Lynch-like» endometrial carcinomas identified on universal screening using mismatch repair protein immunohistochemistry. Am J Surg Pathol 2016; 40: 155 – 165.; Gan C, Love C, Beshay V, et al. Applicability of next generation sequencing technology in microsatellite instability testing. Genes 2015; 6: 46 – 59.; Vanderwalde A, Spetzler D, Xiao N, et al. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med 2018; 7: 746 – 756.; Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite instability across 18 cancer types. Nat Med. 2016 Nov;22 (11):1342 – 1350.; Zaanan A, Shi Q, Taieb J, et al. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. JAMA Oncol. 2018 Mar 1;4 (3):379 – 383.; Sargent DJ, Shi Q, Yothers G., et al. Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II / III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database. DOI:10.1200 / jco. 2014.32.15_suppl. 3507 Journal of Clinical Oncology 32, no. 15_suppl (May 20 2014) 3507 – 3507.; André T, de Gramont A, Vernerey D, et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10‑Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol. 2015 Dec 10;33 (35):4176 – 87.; Pietrantonio F, Raimondi A, Choi YY. MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs). DOI:10.1200 / JCO. 2019.37.4_suppl. 66 Journal of Clinical Oncology 37, no. 4_suppl (February 1 2019) 66 – 66.; Venderbosch S, Nagtegaal ID, Maughan TS et al. Mismatch repair statusand BRAF mutation status in metastatic colorectal cancer patients: apooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20 (20): 5322 – 5330.; Taieb J, Shi Q, Pederson L, et al. Prognosis of microsatellite instability and / or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an accent pooled analysis of 7 studies. Ann Oncol. 2019 Jul 3. pii: mdz208. doi:10.1093 / annonc / mdz208. [Epub ahead of print].; Innocenti F, Ou FS, Qu X, et al. Mutational Analysis of Patients With Colorectal Cancer in CALGB / SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. J Clin Oncol. 2019 May 10;37 (14):1217 – 1227.; Diaz-Padilla I, Romero N, Amir E. Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2013,88 (1):154 – 167.; C. L. Creutzberg, A. Leon-Castillo, S. M. de Boer, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on adjuvant therapy. Annals of Oncology (2019) 30 (suppl_5): v851‑v934. 10.1093 / annonc / mdz394.; Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509 – 2520.; Le DT, Durham JN, Smith KN, et al. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017 Jul 28; 357 (6349): 409 – 413.; Le D, Kavan P, Kim T, et al. Safety and antitumor activity of pembrolizumab in patients with advanced microsatellite instability — high (MSI-H) colorectal cancer: KEYNOTE-164. Ann Oncol. 2018;29 (suppl 5):abstr 0 – 021.; Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair deficient / microsatellite instability — high colorectal cancer (CheckMate 142): results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep; 18 (9): 1182 – 1191.; Overman MJ, Lonardi S, KYM W, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient / microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36 (8):773 – 9.; H-J J Lenz, E Van Cutsem, M L Limon, et al. Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high / mismatch repair deficient (MSI-H / dMMR) metastatic colorectal cancer (mCRC). Ann Oncol, 2018, 29 (8), mdy424.019, https://doi.org / 10.1093 / annonc / mdy424.019.; Hochster HS, Bendell JC, Cleary JM et al. Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite nstability (MSI) — high metastatic colorectal cancer (mCRC). Presented at: AmericanSociety of Clinical Oncology Gastrointestinal Cancers Symposium; January 19 – 21, 2017; San Francisco, CA. 2017; abstract 673.; Eng C, Kim TW, Bendell J, et al. Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2019 Jun;20 (6):849 – 861.; Chalabi M, Fanchi LF, Van den Berg JG, et al. Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer. Ann Oncol. 2018;29 (suppl 8):abstr LBA37.; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Colon Cancer. Version 2.2019. https://www.nccn.org / professionals / physician_gls / pdf / colon. pdf.; Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538–12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Dec 2;390 (10111):2461 – 2471.; Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018 May 10;4 (5):e180013.; Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018 Jul 14;392 (10142):123 – 133.; Tabernero J, Van Cutsem E, Bang Y, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G / GEJ) adenocarcinoma: The phase III KEYNOTE-062 study. J Clin Oncol 2019,37, (suppl; abstr LBA4007).; Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. J Clin Oncol 2018;36:2836 – 44.; Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nature Medicine 2018, 24 (9):1449 – 1458.; Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent / Persistent Endometrial Cancer. J Clin Oncol. 2019 Oct 20;37 (30):2786 – 2794.; Santin AD, Bellone S, Buza N, et al. Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab. Clin Cancer Res. 2016 Dec 1;22 (23):5682 – 5687.; Fleming G, Emens L, Eder J, et al. Clinical activity, safety and biomarker results from a phase Ia study of atezolizumab (atezo) in advanced / recurrent endometrial cancer (rEC). J Clin Oncol 2017, 35 (15): 5585 – 5585.; Makker V., Taylor M. H., Aghajanian C., et al. Lenvatinib (LEN) and Pembrolizumab (PEMBRO) in Advanced Endometrial Cancer (EC). Annals of Oncology (2019) 30 (suppl_5): v403‑v434. 10.1093 / annonc / mdz250.; Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). J Clin Oncol 2019, 37 (15) _suppl: abstr. 2522, doi:10.1200 / JCO. 2019.37.15_suppl. 2522.; Diaz L. A., Le D., Maio M., et al. Pembrolizumab in microsatellite instability high cancers: updated analysis of the phase 2 KEYNOTE-164 and KEYNOTE-158 studies. Annals of Oncology (2019) 30 (suppl_5): v475‑v532. 10.1093 / annonc / mdz253.; Федянин М. Ю., Строгонова А. М., Сендерович А. И., с соавт. Изучение конкордантности мутационного статуса генов KRAS, NRAS, BRAF, PIK3CA между первичной опухолью и метастазами рака толстой кишки. Злокачественные опухоли. 2017; (2):6 – 13.; Chapusot C, Martin L, Bouvier AM, et al. Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas. Br J Canc 2002;87:400e4.; Fujiyoshi K, Yamamoto G, Takahashi A, et al. High concordance rate of KRAS / BRAF mutations and MSI-H between primary colorectal cancer and corresponding metastases. Oncol Rep. 2017 Feb;37 (2):785 – 792.; Sagaert X, Tejpar S, Desmedt L, et al. Intratumoral heterogeneity in colorectal cancer: Can histology be used as a guidance for molecular testing? Journal of Clinical Oncology 35, no. 4_suppl (February 1 2017) 611 – 611.; Jung J, Kang 1, Lee YJ, Kim E, et al. Comparison of the Mismatch Repair System between Primary and Metastatic Colorectal Cancers Using Immunohistochemistry. J Pathol Transl Med. 2017 Mar;51 (2):129 – 136.; Cohen R, Hain E, Buhard O, et al. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status. JAMA Oncol. 2019 Apr 1;5 (4):551 – 555.; Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017 Dec 21;377 (25):2500 – 2501.; Samstein R, Lee CH, Shoushtari A, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019,51:202 – 206.; Schrock AB, Ouyang C, Sandhu J, et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019 Apr 30. pii: mdz134. doi:10.1093 / annonc / mdz134.; https://www.malignanttumors.org/jour/article/view/687

الاتاحة: https://www.malignanttumors.org/jour/article/view/687
https://doi.org/10.18027/2224-5057-2019-9-4-59-69

المؤلفون: A. I. Kalinkin, V. O. Sigin, E. O. Ignatova, M. A. Frolova, E. B. Kuznetsova, I. Y. Vinogradov, M. I. Vinogradov, I. I. Vinogradov, M. V. Nemtsova, D. V. Zaletaev, A. S. Tanas, V. V. Strelnikov

المصدر: Russian Journal of Genetics. 58:835-843

مصطلحات موضوعية: Genetics

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::95a207d0b897c4a3fb320ece83de6bc3
https://doi.org/10.1134/s1022795422070080

المؤلفون: E. A. Ignatova, O. I. Kuznetsova, A. V. Fedorova, M. S. Ignatov

المصدر: Arctoa. 31:7-16

مصطلحات موضوعية: Plant Science, Ecology, Evolution, Behavior and Systematics

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::75d73ba9f369898c59150d259830ef84
https://doi.org/10.15298/arctoa.31.02

المؤلفون: O. Yu. Pisarenko, O. I. Kuznetsova, E. A. Ignatova, M. S. Ignatov

المصدر: Arctoa. 31:1-6

مصطلحات موضوعية: Plant Science, Ecology, Evolution, Behavior and Systematics

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::621b839e5b05bed794cffdc3e0b1c114
https://doi.org/10.15298/arctoa.31.01

المؤلفون: E. A. Ignatova, O. I. Kuznetsova, M. S. Ignatov

المصدر: Arctoa. 31:17-21

مصطلحات موضوعية: Plant Science, Ecology, Evolution, Behavior and Systematics

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::d9ec68ad12beda173d986035655a36e5
https://doi.org/10.15298/arctoa.31.03